<DOC>
	<DOCNO>NCT02675023</DOCNO>
	<brief_summary>This study assess pharmacokinetic ( PK ) safety single 0.8 mL ( 40 mg ) subcutaneous ( SC ) dose M923 administer via auto-injector ( AI ) prefilled syringe ( PFS ) healthy subject .</brief_summary>
	<brief_title>Assessment Pharmacokinetics Safety M923 Administered Via Auto-injector Prefilled Syringe , Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>1 . Healthy male female participant age 18 55 year , inclusive 2 . Healthy participant determine prestudy medical history , physical examination , vital sign 12lead electrocardiogram ( ECG ) 3 . Participants clinical laboratory test result clinically significant acceptable investigator screen admission study site ( Day 1 ) 4 . Participants body weight 60.0 kg 100.0 kg body mass index 18.5 kg/m2 34.9 kg/m2 , inclusive 5 . Healthy male participant must willing comply contraception restriction study . Male participant nonpregnant female partner childbearing potential avoid conception child study ( Day 71 postdose ) 90 day thereafter . 6 . Healthy female participant must negative pregnancy test screen admission study site ( Day 1 ) , must lactate must use acceptable method contraception throughout study 30 day study completion , nonchildbearing potential . Nonpregnant female partner male participant childbearing potential use effective form contraception . 7 . Participants smoke ≤10 cigarette 3 cigar 3 pipes/day least 3 month prior screen willing comply smoking restriction residency study site 8 . Participants able understand provide write informed consent include signature inform consent form ( ICF ) approve Ethics Committee ( EC ) / Institutional Review Board ( IRB ) 9 . Participants provide write authorization use disclosure protect health information 10 . Participants agree abide study schedule dietary restriction return require assessment 1 . History and/or current presence clinically significant angioedema , eczematous dermatitis require prescription medication , clinically significant hypersensitivity , severe allergic reaction ( either spontaneous follow IP administration ) , also include know suspected clinically relevant drug hypersensitivity component IP comparable drug , include latex 2 . Active latent tuberculosis history TB . 3 . History invasive and/or active systemic fungal infection severe opportunistic infection , include recurrent clinically significant chronic local fungal infection 4 . A serious infection within 6 month prior investigational product ( IP ) administration and/or infection within 2 week screen screen period unless resolve completely within 2 week admission study site Day 1 5 . Herpes zoster infection last year 2 herpes zoster infection his/her lifetime 6 . Frequent chronic recurrent infection ( define &gt; 3 year require prescribed treatment ) 7 . Previous use adalimumab , HUMIRA® , another recombinant human monoclonal antibody 8 . Intake investigational drug another study within 30 day ( 5 halflives , whichever great ) prior intake IP study receive last dose study drug 30 day ago ( 5 halflives , whichever great ) extend followup , plan intake investigational drug ( study ) course study 9 . History alcohol abuse year precede screen visit , history excess alcohol consumption . 10 . Known history opioid cocaine drug abuse drug abuse past year positive test drug abuse alcohol screen admission study site ( Day 1 ) 11 . Donation blood blood product ( eg , plasma , platelet ) within 30 day prior IP administration 12 . Use prescribed nonprescribed medication include antacid , analgesic ( paracetamol/acetaminophen ) , dietary supplement herbal medication 2 week prior IP administration long medication long halflife . Use medication deem necessary participant 's physician treat prevent medical condition , paracetamol/acetaminophen ≤3 g/day use vitamin daily recommend dos allow ; female volunteer , oral birth control hormone replacement therapy allow 13 . History exist congestive heart failure 14 . History exist sign symptom demyelinate disease optic neuritis and/or multiple sclerosis 15 . History cancer include lymphoma , leukemia , skin cancer cervical carcinoma situ 16 . Impaired liver function 17 . History immunodeficiency ( include participant positive test human immunodeficiency virus [ HIV ] I II screen ) clinically significant immunological disorder , autoimmune disorder , ( eg , rheumatoid arthritis , lupus erythematosus , scleroderma , psoriasis ) 18 . Positive test anticitrullinated protein antibody screen 19 . Clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , hematological ( include pancytopenia , aplastic anemia , blood dyscrasia ) , metabolic ( include know diabetes mellitus ) , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue diseases disorder judge investigator 20 . Received live vaccine within 12 week prior admission study site ( Day 1 ) plan receive live vaccine study ( include Day 71 ) 21 . Volunteers vegans medical dietary restriction 22 . Volunteers communicate reliably investigator 23 . Volunteer family member employee investigator study site staff study team</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>